Next Article in Journal
Systemic Therapy for Recurrent, Persistent, or Metastatic Cervical Cancer: A Clinical Practice Guideline
Previous Article in Journal
Using Proliferative Markers and Oncotype Dx in Therapeutic Decision-Making for Breast Cancer: The B.C. Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 3
10.3747/co.22.2395
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ondansetron Rapidly Dissolving Film for the Prophylactic Treatment of Radiation-Induced Nausea and Vomiting—A Pilot Study

by
E. Wong
,
N. Pulenzas
,
G. Bedard
,
C. DeAngelis
,
L. Zhang
,
M. Tsao
,
C. Danjoux
,
N. Thavarajah
,
B. Lechner
,
R. McDonald
,
P.M. Cheon
and
E. Chow
*
Rapid Response Radiotherapy Program, Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(3), 199-210; https://doi.org/10.3747/co.22.2395
Submission received: 3 March 2015 / Revised: 6 April 2015 / Accepted: 9 May 2015 / Published: 1 June 2015

Abstract

Introduction: The purpose of the present study was to investigate the efficacy of an ondansetron rapidly dissolving film (RDF) in the prophylaxis of radiation-induced nausea and vomiting (RINV). Rapidly dissolving film formulations facilitate drug delivery in circumstances in which swallowing the medication might be difficult for the patient. Methods: Patients undergoing palliative radiotherapy at risk for RINV were prescribed ondansetron RDF 8 mg twice daily while on treatment and were asked to complete a nausea and vomiting–specific daily diary, the Functional Living Index–Emesis (FLIE), and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–C15 Palliative (QLQ-C15-PAL). Patients were categorized as receiving primary or secondary prophylaxis based on whether they had already experienced emetic episodes. “Overall control” was defined as a maximum increase of 2 episodes of nausea or vomiting from baseline. “Acute phase” was defined as the days during radiation until the first day after radiation; “delayed phase” was defined as days 2–10 after radiation. Results: The study accrued 30 patients. Rates of overall control for nausea and for vomiting during the acute phase in the primary prophylaxis group were 88% and 93% respectively; during the delayed phase, they were 73% and 75%. Rates of overall control for nausea and for vomiting during the acute phase in the secondary prophylaxis group were both 100%; during the delayed phase, they were 50%. The number of nausea and vomiting episodes was found to be significantly correlated with the flie and QLQ-C15-PAL questionnaires. Conclusions: Ondansetron rdf is effective for the prophylaxis of RINV.
Keywords: radiation-induced nausea and vomiting; prophylaxis; ondansetron; rapidly dissolving film radiation-induced nausea and vomiting; prophylaxis; ondansetron; rapidly dissolving film

Share and Cite

MDPI and ACS Style

Wong, E.; Pulenzas, N.; Bedard, G.; DeAngelis, C.; Zhang, L.; Tsao, M.; Danjoux, C.; Thavarajah, N.; Lechner, B.; McDonald, R.; et al. Ondansetron Rapidly Dissolving Film for the Prophylactic Treatment of Radiation-Induced Nausea and Vomiting—A Pilot Study. Curr. Oncol. 2015, 22, 199-210. https://doi.org/10.3747/co.22.2395

AMA Style

Wong E, Pulenzas N, Bedard G, DeAngelis C, Zhang L, Tsao M, Danjoux C, Thavarajah N, Lechner B, McDonald R, et al. Ondansetron Rapidly Dissolving Film for the Prophylactic Treatment of Radiation-Induced Nausea and Vomiting—A Pilot Study. Current Oncology. 2015; 22(3):199-210. https://doi.org/10.3747/co.22.2395

Chicago/Turabian Style

Wong, E., N. Pulenzas, G. Bedard, C. DeAngelis, L. Zhang, M. Tsao, C. Danjoux, N. Thavarajah, B. Lechner, R. McDonald, and et al. 2015. "Ondansetron Rapidly Dissolving Film for the Prophylactic Treatment of Radiation-Induced Nausea and Vomiting—A Pilot Study" Current Oncology 22, no. 3: 199-210. https://doi.org/10.3747/co.22.2395

APA Style

Wong, E., Pulenzas, N., Bedard, G., DeAngelis, C., Zhang, L., Tsao, M., Danjoux, C., Thavarajah, N., Lechner, B., McDonald, R., Cheon, P. M., & Chow, E. (2015). Ondansetron Rapidly Dissolving Film for the Prophylactic Treatment of Radiation-Induced Nausea and Vomiting—A Pilot Study. Current Oncology, 22(3), 199-210. https://doi.org/10.3747/co.22.2395

Article Metrics

Back to TopTop